Innate Pharma SA Files 6-K with Q2 2025 Financials
Ticker: IPHYF · Form: 6-K · Filed: Sep 17, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Sep 17, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing, shares
TL;DR
Innate Pharma dropped Q2 2025 financials, showing share capital details.
AI Summary
Innate Pharma SA filed a 6-K report on September 17, 2025, detailing financial information as of June 30, 2025. The report includes data on ordinary and preference shares, share premium, and issued capital for the periods ending December 31, 2023, and June 30, 2025. Key financial figures and share structures are presented for the fiscal year ending December 31.
Why It Matters
This filing provides investors with an update on Innate Pharma's financial position and share structure as of mid-2025, crucial for assessing the company's stability and potential.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) providing standard disclosures without significant new events or market-moving information.
Key Numbers
- 20250630 — Reporting Period End Date (Indicates the latest financial data available in this filing.)
- 2023-12-31 — Previous Year End Date (Provides a comparative financial snapshot from the prior year.)
Key Players & Entities
- Innate Pharma SA (company) — Filer of the report
- 0001598599-25-000075 (filing_id) — Accession number for the filing
- 20250917 (date) — Filing date
- 20250630 (date) — Reporting period end date
- 2023-12-31 (date) — Previous reporting period end date
FAQ
What is the primary purpose of this 6-K filing by Innate Pharma SA?
The primary purpose is to provide updated financial information and disclosures for the period ending June 30, 2025, as required by the SEC.
What specific financial periods are covered in the data presented?
The filing presents data for the period ending June 30, 2025, and comparative data for December 31, 2023, and June 30, 2024.
What type of shares are mentioned in the filing?
The filing mentions ordinary shares and preference shares, specifically related to issued capital.
When was this 6-K report filed with the SEC?
This 6-K report was filed on September 17, 2025.
What is Innate Pharma SA's primary business sector?
Innate Pharma SA operates in the Biological Products sector, specifically excluding diagnostic substances, as indicated by its SIC code 2836.
Filing Stats: 269 words · 1 min read · ~1 pages · Grade level 11.4 · Accepted 2025-09-17 06:24:13
Filing Documents
- inpha-20250630.htm (6-K) — 261KB
- inpha-20250630_d2.htm (EX-99.2) — 1335KB
- 0001598599-25-000075.txt ( ) — 9438KB
- inpha-20250630.xsd (EX-101.SCH) — 104KB
- inpha-20250630_cal.xml (EX-101.CAL) — 100KB
- inpha-20250630_def.xml (EX-101.DEF) — 346KB
- inpha-20250630_lab.xml (EX-101.LAB) — 752KB
- inpha-20250630_pre.xml (EX-101.PRE) — 538KB
- inpha-20250630_htm.xml (XML) — 1874KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date: September 17, 2025 By: /s/ Jonathan DICKINSON Name: Jonathan DICKINSON Title: Chief Executive Officer